BC
AXSM icon

Birchview Capital’s Axsome Therapeutics AXSM Stock Holding History

Birchview Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Hold
6,000
– – 0.69% 34
2026
Q1 		$1.01M Sell
6,000
-61
-1% -$10.5K 0.58% 41
2025
Q4 		$1.11M Buy
6,061
+61
+1% +$8.52K 0.65% 37
2025
Q3 		$729K Hold
6,000
– – 0.55% 43
2025
Q2 		$626K Hold
6,000
– – 0.62% 36
2025
Q1 		$700K Buy
6,000
+2,000
+50% +$228K 0.61% 27
2024
Q4 		$338K Hold
4,000
– – 0.28% 46
2024
Q3 		$359K Hold
4,000
– – 0.31% 40
2024
Q2 		$322K Hold
4,000
– – 0.3% 42
2024
Q1 		$319K Buy
+4,000
New +$336K 0.26% 46

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Birchview Capital's AXSM Position: Q2 2026 in Review

Birchview Capital held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 6,000 shares worth $1.47M. The position accounts for 0.69% of the portfolio, ranked #34.

Birchview Capital first reported a position in AXSM in Q1 2024 and has held it in 10 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Birchview Capital held 6,000 shares of Axsome Therapeutics worth $1.47M as of Q2 2026.
  • Birchview Capital left its Axsome Therapeutics share count unchanged in Q2 2026.
  • Axsome Therapeutics made up 0.69% of Birchview Capital's portfolio in Q2 2026, its #34 holding.
  • Birchview Capital first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.